Phase II trials and stem cell therapies
There are more than a dozen or so treatments in Phase II trials, including agonists for PPAR and farnesoid X receptors, such as Enanta’s EDP 305.
Enanta plans to start a further Phase III trial ARGON-2 in NASH in early Q2 2020 and start a Phase I study of EDP 297 as a follow up FXR agonist.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Welcome to the Fluid Management Learning Zone. In this Learning Zone we provide an overview of fluid management, including albumin for sepsis and septic shock, guidelines for fluid management in liver cirrhosis and fluid management in cardiac surgery.
Related news and insights
Developed by EPG Health for Medthority in collaboration with Biogen®. This content is intended for healthcare professionals only, and it has been funded and reviewed by Biogen® for scientific accuracy.